{"gene":"TIMP1","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2000,"finding":"TIMP-1 inhibits the catalytic activity of ADAM-10 with an apparent inhibition constant of approximately 0.1 nM, as measured by a quenched fluorescent substrate assay, distinguishing ADAM-10 inhibition from TACE (which is only inhibited by TIMP-3).","method":"In vitro enzyme inhibition assay (quenched fluorescent substrate assay) with recombinant proteins","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro biochemical assay with recombinant catalytic domain and quantified Ki, single lab but rigorous enzyme kinetics","pmids":["10818225"],"is_preprint":false},{"year":1996,"finding":"TIMP-1 is a slow, tight-binding inhibitor of fibroblast-type collagenase (MMP-1) operating via a noncompetitive two-step mechanism: rapid formation of a reversible complex (Kd ~8 nM) followed by slow formation of a tight complex (global Kd ~0.1 nM). The C-terminal domain of collagenase is required for the initial rapid binding step.","method":"Enzyme kinetics — time-course inhibition assays analyzed by nonlinear regression and numerical integration; comparison with C-terminal domain-truncated 'mini-collagenase'","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted in vitro kinetic analysis with multiple analytical methods, truncation mutant validation","pmids":["8798626"],"is_preprint":false},{"year":2005,"finding":"TIMP-1 negatively regulates hepatocyte growth factor (HGF) activity during liver regeneration: TIMP-1 loss-of-function in Timp-1−/− mice elevated MMP activity and increased active HGF, leading to enhanced phosphorylation of Met and its downstream effector p38, accelerating hepatocyte cell cycle progression (earlier cyclin D1, PCNA, phospho-histone H3). Conversely, TIMP-1 gain-of-function delayed cell cycle progression.","method":"Genetic loss-of-function (Timp-1−/− mice) and gain-of-function (transgenic overexpression); real-time RT-PCR; immunostaining for cell cycle markers and phospho-Met","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain- and loss-of-function genetic models with multiple orthogonal cell-cycle readouts and pathway (HGF/Met/p38) placement","pmids":["15726641"],"is_preprint":false},{"year":2008,"finding":"TIMP-1 binds specifically to proMMP-9 at the cell surface, where proMMP-9 is anchored to the plasma membrane via CD44. Formation of this ternary TIMP-1/proMMP-9/CD44 complex is necessary for TIMP-1-induced anti-apoptotic signaling (JAK2/PI3K/Akt pathway) in UT-7 erythroid cells; silencing proMMP-9 abrogated the TIMP-1 survival effect, and MMP-9-function-blocking antibodies that prevent TIMP-1 binding also abolished cell survival without reproducing the effect themselves.","method":"Co-immunoprecipitation, proMMP-9 siRNA knockdown, MMP-9 function-blocking antibodies, synthetic MMP inhibitor, cell survival assays","journal":"The international journal of biochemistry & cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, multiple knockdown/blocking approaches, clear mechanistic pathway placement, single lab","pmids":["19010442"],"is_preprint":false},{"year":2011,"finding":"Tumor cell-derived TIMP-1 maintains Met receptor signaling by inhibiting ADAM-10-mediated shedding of Met; knockdown of tumor-cell Timp-1 suppressed Met phosphorylation and HGF-induced Met activation, whereas knockdown of ADAM-10 mimicked Timp-1 overexpression by increasing Met phosphorylation and tumor cell scattering in the liver.","method":"siRNA knockdown of Timp-1 and Adam-10 in syngeneic murine experimental liver metastasis model; in vitro Met phosphorylation assays; immunolocalization in metastatic foci","journal":"Clinical & experimental metastasis","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo knockdown with in vitro mechanistic validation, parallel Adam-10 knockdown epistasis, single lab","pmids":["21789719"],"is_preprint":false},{"year":2013,"finding":"TIMP-1 binding to its surface receptor CD63 activates intracellular signaling that induces EMT in human breast epithelial MCF10A cells, evidenced by loss of E-cadherin and gain of vimentin, N-cadherin, and fibronectin, through upregulation of the transcription factor TWIST1; RNAi knockdown of TWIST1 rescued E-cadherin expression. This function is independent of TIMP-1's MMP-inhibitory domain, as demonstrated with structural TIMP-1 mutants.","method":"TIMP-1 overexpression, RNAi knockdown of TWIST1, structural MMP-inhibitory domain mutants, immunofluorescence for EMT markers","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic rescue (TWIST1 knockdown restores E-cadherin), domain mutant establishes MMP-independence, multiple orthogonal markers, single lab","pmids":["24895412"],"is_preprint":false},{"year":2014,"finding":"TIMP-1 signals through CD63 to activate β1-integrin-mediated Akt and FAK phosphorylation, promoting adhesion and chemotaxis of human neural stem cells (hNSCs); shRNA silencing of CD63 or blocking of β1-integrin abrogated the TIMP-1-induced migration, focal adhesion formation, and cytoskeletal reorganization.","method":"shRNA knockdown of CD63, β1-integrin blocking antibody, PI3K inhibitor, migration assays, immunofluorescence for focal adhesions and F-actin","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological dissection of CD63/β1-integrin/Akt/FAK signaling axis, multiple orthogonal methods, single lab","pmids":["24635319"],"is_preprint":false},{"year":2015,"finding":"TIMP-1 triggers granulopoiesis and neutrophilia via CD63-mediated signaling: elevated systemic TIMP-1 increased myeloid progenitor proliferation (BrdU incorporation) and granulopoiesis gene expression in bone marrow. TIMP-1 variants with intact CD63-binding (signaling) domain but lacking MMP-inhibitory activity were sufficient to induce neutrophilia, and genetic ablation of CD63 abolished both TIMP-1-induced neutrophilia and granulopoiesis.","method":"In vivo TIMP-1 elevation in mice; BrdU pulse-labeling; TIMP-1 functional domain variants; CD63 knockout mice","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain-dissecting TIMP-1 variants combined with CD63 knockout, BrdU proliferation assay, clear in vivo phenotype, multiple orthogonal methods","pmids":["26001794"],"is_preprint":false},{"year":2015,"finding":"TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate cells (HSCs) and hepatocellular carcinoma (HCC) cells by activating FAK signaling via interaction with CD63: TGF-β signaling in HSCs increased TIMP-1 secretion, which then activated FAK in HCC cells; this promoted HCC proliferation, motility, and survival.","method":"Conditioned medium experiments, TGF-β signaling inhibition (EW-7197), in vivo orthotopic xenograft model, FAK/Akt signaling assessment","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vivo orthotopic model with pharmacological inhibition, mechanistic pathway (TGF-β/TIMP-1/CD63/FAK) placed, single lab, limited genetic dissection of TIMP-1 interaction","pmids":["26549110"],"is_preprint":false},{"year":2011,"finding":"BRAF(V600E) mutation in papillary thyroid carcinoma activates NF-κB, which upregulates TIMP-1; TIMP-1 then binds its surface receptor CD63, activating Akt signaling and conferring anti-apoptotic behavior. Silencing BRAF in BCPAP cells (harboring BRAF(V600E)) reduced TIMP-1 expression and NF-κB activity; sorafenib (but not MEK inhibitor) inhibited both NF-κB and TIMP-1/Akt signaling, indicating the pathway is MEK-independent.","method":"siRNA knockdown of BRAF, specific pathway inhibitors, luciferase NF-κB reporter, invasion assays, immunohistochemistry in 56 PTC specimens","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown plus pharmacological epistasis, pathway placement (BRAF→NF-κB→TIMP-1→CD63→Akt), single lab","pmids":["21903858"],"is_preprint":false},{"year":2004,"finding":"TIMP-1 inhibits endothelial cell migration through two distinct mechanisms: (1) MMP-dependent pathway involving increased expression and junctional accumulation of VE-cadherin and PECAM-1; (2) MMP-independent pathway involving stimulation of PTEN expression with subsequent dephosphorylation of focal adhesion kinase (FAK, pY397) and paxillin and reduction of F-actin stress fibers and focal adhesions.","method":"Recombinant TIMP-1 and synthetic MMP inhibitor treatment; immunofluorescence; Western blot for FAK, paxillin, PTEN, VE-cadherin, PECAM-1","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — parallel use of recombinant TIMP-1 and synthetic MMP inhibitors to dissect MMP-dependent vs independent pathways, multiple protein readouts, single lab","pmids":["15530852"],"is_preprint":false},{"year":2018,"finding":"TIMP-1 promotes oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes via a CD63/β1-integrin receptor complex that activates Akt and downstream β-catenin signaling; this trophic action is independent of TIMP-1's MMP-inhibitory function, and was counteracted (but not abolished) by canonical Wnt7a signaling.","method":"Pharmacological inhibitors, receptor blocking, signaling pathway analysis (Akt, β-catenin), comparison with MMP-inhibitory function","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — identification of CD63/β1-integrin/Akt/β-catenin pathway, MMP-independence established, single lab with multiple pathway readouts","pmids":["30121936"],"is_preprint":false},{"year":2019,"finding":"Toxoplasma gondii-induced TIMP-1 secretion from dendritic cells drives DC hypermotility via a CD63-ITGB1(β1-integrin)-FAK signaling axis; shRNA silencing of TIMP-1, CD63, or ITGB1, and pharmacological inhibition of FAK, SRC, or PI3K each abolished parasite-induced DC hypermotility.","method":"shRNA gene silencing of TIMP-1, CD63, ITGB1, FAK; pharmacological antagonism of FAK, SRC, PI3K; DC migration assays","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple independent genetic knockdowns and pharmacological inhibitors converging on TIMP-1→CD63→ITGB1→FAK axis, rigorous controls","pmids":["30635444"],"is_preprint":false},{"year":2013,"finding":"TIMP-1 inhibits MMP activity in epileptic conditions, thereby preventing proteolytic processing of Reelin; kainate treatment upregulated TIMP-1 in hippocampal neurons, functional inhibition of TIMP-1 prevented kainate-induced impairment of Reelin cleavage, and application of recombinant TIMP-1 alone was sufficient to impair Reelin processing and induce granule cell dispersion (GCD).","method":"Organotypic hippocampal slice cultures, kainate epilepsy model, TIMP-1 functional inhibition, recombinant TIMP-1 application, immunolabeling for TIMP-1 and Reelin processing","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function of TIMP-1 with specific Reelin cleavage readout, single lab","pmids":["23493620"],"is_preprint":false},{"year":2023,"finding":"TIMP-1 is a novel ligand for Amyloid Precursor Protein (APP) and APP-like protein 2 (APLP2); TIMP-1 binding to APP on human monocytes triggers glucose uptake and proinflammatory cytokine expression. Mechanistically, TIMP-1 acts via its C-terminal domain and through APP, as demonstrated by recombinant TIMP-1 C-terminal domain variants and in silico docking, and confirmed by unbiased ligand-receptor capture screening, pull-down assays, and confocal microscopy.","method":"Unbiased ligand-receptor capture screening, pull-down assays, confocal microscopy, recombinant TIMP-1 domain variants, in silico docking, glucose uptake assay, cytokine expression","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal biochemical methods (pull-down, proximity assay, confocal) plus functional domain dissection, unbiased discovery approach, single lab","pmids":["36629908"],"is_preprint":false},{"year":2023,"finding":"ADAMTS-7 degrades TIMP-1 by direct binding via its catalytic domain (demonstrated by co-immunoprecipitation and in vitro degradation assays), thereby reducing TIMP-1's inhibitory capacity toward MMP-9 and increasing collagen degradation in atherosclerotic plaques.","method":"Co-immunoprecipitation, in vitro degradation assay, FRET-based protein-protein interaction assay, mass spectrometry of atherosclerotic plaques from Apoe−/−Adamts7−/− vs. Apoe−/− mice, Picrosirius red collagen staining","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro reconstitution of ADAMTS-7-mediated TIMP-1 degradation plus Co-IP binding, multiple orthogonal methods, in vivo validation in double-KO mice","pmids":["37675562"],"is_preprint":false},{"year":2022,"finding":"In lung adenocarcinoma, TIMP-1 overexpression in tumor-associated fibroblasts (TAFs) is driven specifically by the TGF-β1/SMAD3 pathway; fibroblast-secreted TIMP-1 enhances growth and invasion of ADC cancer cells in a manner requiring cancer cell surface receptor CD63; SMAD3 or TIMP-1 knockdown in TAFs attenuated tumor aggressiveness in vivo.","method":"shRNA/siRNA knockdown of SMAD3, TIMP-1, CD63; co-culture assays; in vivo co-injection xenograft model; gene expression analyses in human ADC vs SCC specimens","journal":"Matrix biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — in vivo genetic validation with both stromal and cancer cell genetic knockdowns, CD63 dependency established, TGF-β1/SMAD3 pathway mechanistically placed, single lab","pmids":["35787446"],"is_preprint":false},{"year":2015,"finding":"TIMP-1 inhibits apoptosis in lung adenocarcinoma cells via interaction with Bcl-2 (demonstrated by co-immunoprecipitation) and activation of p90RSK with phosphorylation of BAD at serine 112, reducing Bax levels and increasing mitochondrial permeability; this anti-apoptotic function is independent of MMP inhibition (TIMP-1 T2G mutant lacking MMP inhibitory activity retains full anti-apoptotic effect).","method":"Co-immunoprecipitation, TIMP-1 T2G structural mutant (MMP-inhibitory domain ablated), Western blot for PARP cleavage/BAD phosphorylation/Bax, staurosporine apoptosis assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — domain-dissecting mutant establishes MMP-independence, Co-IP for TIMP-1/Bcl-2 interaction, downstream pathway (p90RSK/BAD/Bax) validated, single lab","pmids":["26366732"],"is_preprint":false},{"year":2002,"finding":"STAT1 and STAT3 mediate thrombin-induced TIMP-1 gene transcription in human glomerular mesangial cells; thrombin induced STAT-DNA binding activity, and antisense oligonucleotides against STAT1 or STAT3 inhibited both STAT-DNA binding and TIMP-1 mRNA expression; the SIF band on EMSA contained both STAT1 and STAT3.","method":"Northern blot, EMSA, supershift assay, antisense oligonucleotides for STAT1 and STAT3","journal":"Kidney international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus antisense knockdown with transcriptional readout, supershift confirms STAT proteins, single lab","pmids":["11918744"],"is_preprint":false},{"year":1993,"finding":"Recombinant TIMP-1 (and TIMP-2) inhibit stimulated bone resorption (induced by PTH or 1,25-dihydroxyvitamin D3) in cultured neonatal mouse calvariae in a dose-dependent, reversible manner, with complete inhibition at 1 μg/ml; neither TIMP affected protein synthesis, DNA synthesis, or PTH-enhanced β-glucuronidase secretion, suggesting the inhibitory effect is targeted at matrix metalloproteinase-mediated resorption steps.","method":"Recombinant protein treatment in organ culture (calvarial bone resorption assay); dose-response analysis; controls for cell toxicity and PTH signaling","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro organ culture with dose-response and multiple control readouts, single lab, recombinant protein","pmids":["8485170"],"is_preprint":false},{"year":2013,"finding":"TIMP-1-overexpressing cancer cells exhibit increased expression and phosphorylation of topoisomerases 1, 2A, and 2B, which correlates with resistance to topoisomerase inhibitors; pathway analysis implicates protein kinases CK2a, CDK1, PLK1, and ATM in topoisomerase hyperphosphorylation in TIMP-1-high MCF-7 cells.","method":"SILAC-based quantitative mass spectrometry of global proteome and phosphoproteome in TIMP-1-high vs. TIMP-1-low MCF-7 cells; NetworKIN kinase prediction","journal":"Journal of proteome research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — quantitative proteomics/phosphoproteomics is orthogonal and unbiased but kinase assignment is computational; single lab","pmids":["23909892"],"is_preprint":false},{"year":2018,"finding":"TIMP-1 and CD63 proteins are co-expressed at the cellular level in glioblastoma cells, located in close molecular proximity (demonstrated by proximity ligation assay), and co-immunoprecipitate, confirming a physical protein-protein interaction between TIMP-1 and its surface receptor CD63 in glioblastoma.","method":"Proximity ligation assay, co-immunoprecipitation, immunofluorescence co-localization in human glioblastoma tissue","journal":"BMC cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal binding assays (Co-IP + PLA) confirming TIMP-1/CD63 interaction in tissue context, single lab","pmids":["29523123"],"is_preprint":false},{"year":2017,"finding":"CD82 (KAI1/tetraspanin) is a binding partner of TIMP-1 on the surface of pancreatic adenocarcinoma cells; CD82 binds TIMP-1 via its large extracellular loop interacting with the N-terminal region of TIMP-1, co-localizes with TIMP-1, and facilitates membrane-bound TIMP-1 endocytosis, contributing to the anti-migration effect of TIMP-1; CD82 silencing partially eliminates these functions.","method":"Co-immunoprecipitation, co-localization, CD82 siRNA silencing, TIMP-1 endocytosis assay, cell migration assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding shown by Co-IP, domain mapping (N-terminal TIMP-1/EL2 of CD82), genetic knockdown with functional readout, single lab","pmids":["28030805"],"is_preprint":false},{"year":2019,"finding":"TIMP-1 inhibits proliferation and osteogenic differentiation of human bone marrow-derived MSCs (hBMSCs) through the Wnt/β-catenin signaling pathway: TIMP-1 knockdown upregulated β-catenin and cyclin D1, enhanced osteogenic markers (Sox9, osteocalcin, RUNX-2), and restored Dickkopf-1-inhibited β-catenin/cyclin D1/RUNX-2 expression; conversely, TIMP-1 overexpression attenuated Wnt3a-induced β-catenin/cyclin D1/RUNX-2 upregulation.","method":"Stable TIMP-1 overexpression and knockdown in hBMSCs; Alizarin Red S staining; ALP activity; Western blot for β-catenin, cyclin D1, RUNX-2; Wnt3a and Dickkopf-1 pathway manipulation","journal":"Bioscience reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal gain and loss of function with Wnt pathway activator and inhibitor epistasis, multiple osteogenic readouts, single lab","pmids":["30473539"],"is_preprint":false},{"year":2006,"finding":"TIMP-1 gene-deficient fibrosarcoma cells show significantly increased sensitivity to chemotherapy-induced apoptosis compared to genetically identical wild-type cells, demonstrating that endogenous TIMP-1 protects cells from apoptosis independently of exogenous supplementation.","method":"TIMP-1 gene-deficient vs. wild-type fibrosarcoma cells derived from mouse lung tissue; chemotherapy-induced apoptosis assays","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — clean genetic comparison (KO vs WT isogenic cells) with defined apoptosis phenotype, single lab, limited pathway placement in this study","pmids":["17047657"],"is_preprint":false},{"year":2013,"finding":"TIMP-1 promotes cellular proliferation in gastric cancer in an NF-κB-dependent manner: TNF-α and NF-κB activation induced TIMP-1 expression, NF-κB inhibition (BAY11-7082) downregulated TIMP-1, and TFF1 reconstitution suppressed NF-κB and inhibited TIMP-1-mediated proliferative potential (EDU assay).","method":"NF-κB inhibitor BAY11-7082, TFF1 reconstitution with recombinant protein, quantitative RT-PCR, EDU proliferation assay, gastric organoids from Tff1-KO mice","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic manipulation of NF-κB/TIMP-1 axis with functional proliferation readout, confirmed in organoid model, single lab","pmids":["30035371"],"is_preprint":false},{"year":2004,"finding":"Pancreatic cancer-conditioned medium stimulates pancreatic stellate cell (PSC) proliferation and TIMP-1 gene expression through the MAP kinase (ERK1/2) pathway; inhibition of ERK1/2 phosphorylation with U0126 prevented both growth and TIMP-1 upregulation.","method":"PSC culture with PANC-1 conditioned medium, ERK1/2 inhibitor U0126, real-time PCR for TIMP-1 mRNA, DNA synthesis and cell counting","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway inhibition (ERK1/2) with parallel functional (proliferation) and molecular (TIMP-1 mRNA) readouts, single lab","pmids":["15451430"],"is_preprint":false},{"year":2006,"finding":"GPI-anchored TIMP-1 inserted into the plasma membrane of renal cell carcinoma (RCC) cells altered the association of MMPs with the cell surface, inhibited RCC proliferation, and rendered normally FAS-resistant RCC cells sensitive to FAS-induced apoptosis by shifting the balance of pro- and anti-apoptotic BCL-2-family proteins; perforin-mediated lysis was not affected.","method":"GPI-TIMP-1 fusion protein treatment of RCC cell lines; FAS apoptosis assays; perforin lysis assay; BCL-2-family Western blotting","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — engineered TIMP-1-GPI construct to manipulate cell surface MMP balance, separate FAS vs perforin mechanistic dissection, BCL-2 family readout, single lab","pmids":["16261161"],"is_preprint":false},{"year":2013,"finding":"TIMP-1 attenuates blood-brain barrier (BBB) permeability in acute liver failure by inhibiting MMP-9, reducing activation of EGFR and p38 MAPK signaling, and restoring tight junction protein occludin; intracerebroventricular delivery of TIMP-1 cDNA or pegylated TIMP-1 protein provided similar protection.","method":"Intracerebroventricular TIMP-1 cDNA injection and pegylated-TIMP-1 protein treatment in murine ALF model; sodium fluorescein permeability assay; EGFR and p38 MAPK Western blot; occludin immunostaining","journal":"Journal of cerebral blood flow and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo rescue experiments with two delivery strategies (gene and protein), signaling pathway (EGFR/p38) and tight junction (occludin) readouts, single lab","pmids":["23532086"],"is_preprint":false},{"year":2013,"finding":"TIMP-1 promotes cancer associated fibroblast (CAF) accumulation in prostate and colon cancer and enhances CAF proliferation and migration in vitro; TIMP-1 activates ERK1/2 kinase signaling in prostate CAFs.","method":"In vivo tumor growth assays with TIMP-1-overexpressing cells; in vitro CAF proliferation/migration assays; Western blot for ERK1/2 phosphorylation","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro models with ERK1/2 signaling pathway placement, single lab, limited mechanistic depth","pmids":["24143225"],"is_preprint":false},{"year":1999,"finding":"TIMP-1 (and TIMP-2) at nanomolar concentrations stimulate osteoclastic bone resorption in vitro through a mechanism related to the functional activity of osteoclasts (not osteoclast number), which cannot be replicated by synthetic MMP inhibitors, indicating the bone resorption-stimulating activity of TIMP-1 is independent of its MMP-inhibitory effect.","method":"Removal/reconstitution of TIMPs from FCS in osteoclast bone resorption cultures; TRAP-positive cell counting; comparison with synthetic metalloproteinase inhibitors BE16627B and R94138","journal":"Journal of bone and mineral metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reconstitution experiment with recombinant TIMPs and MMP inhibitor controls to dissect mechanism, single lab","pmids":["10575588"],"is_preprint":false}],"current_model":"TIMP-1 is a multifunctional secreted glycoprotein that acts both as an endogenous metalloproteinase inhibitor (blocking MMPs and ADAM-10 via tight-binding inhibition, including a two-step noncompetitive mechanism for collagenase) and as a cytokine-like signaling molecule that binds cell-surface receptors—principally CD63 (and its co-receptors β1-integrin, proMMP-9/CD44), as well as Amyloid Precursor Protein and CD82—to activate intracellular pathways including JAK2/PI3K/Akt, FAK, ERK1/2, Wnt/β-catenin, and STAT1/3, thereby regulating cell survival/apoptosis, proliferation, differentiation (oligodendrocytes, osteoblasts), migration, EMT, granulopoiesis, and immune cell activation independently of its MMP-inhibitory domain."},"narrative":{"mechanistic_narrative":"TIMP-1 is a secreted glycoprotein that operates as both an endogenous metalloproteinase inhibitor and a cytokine-like signaling ligand that controls cell survival, proliferation, differentiation, migration, and immune cell activation [PMID:8798626, PMID:24895412, PMID:26001794]. As a protease inhibitor it is a slow, tight-binding noncompetitive inhibitor of fibroblast collagenase (MMP-1) that engages the enzyme C-terminal domain in an initial rapid step before forming a tight complex [PMID:8798626], and it also inhibits ADAM-10 with sub-nanomolar potency, distinguishing it from TACE [PMID:10818225]. This proteolytic activity tunes substrate availability in tissue contexts: TIMP-1 restrains MMP-mediated generation of active HGF to limit Met/p38-driven hepatocyte cell-cycle progression [PMID:15726641], blocks ADAM-10-mediated shedding of Met to sustain receptor signaling in tumor cells [PMID:21789719], and limits MMP-9 activity to preserve barrier integrity and matrix structure [PMID:23532086, PMID:37675562]. Independently of its MMP-inhibitory domain, TIMP-1 functions as a receptor ligand—principally through the tetraspanin CD63 and its co-receptors β1-integrin and a cell-surface proMMP-9/CD44 complex—to trigger JAK2/PI3K/Akt, FAK, ERK1/2, and Wnt/β-catenin signaling [PMID:19010442, PMID:24635319, PMID:26001794, PMID:30121936]. Through these axes TIMP-1 promotes anti-apoptotic survival signaling [PMID:19010442, PMID:26366732], drives EMT via TWIST1 induction [PMID:24895412], directs adhesion and chemotaxis of neural stem cells and dendritic cells [PMID:24635319, PMID:30635444], stimulates granulopoiesis and neutrophilia [PMID:26001794], and modulates osteogenic and oligodendrocyte differentiation [PMID:30121936, PMID:30473539]. MMP-independence of these signaling outputs is established with structural TIMP-1 mutants lacking inhibitory activity that retain full signaling competence [PMID:24895412, PMID:26001794, PMID:26366732]. Additional surface partners include CD82, which binds the TIMP-1 N-terminus and mediates its endocytosis [PMID:28030805], and APP/APLP2, engaged via the TIMP-1 C-terminal domain to drive monocyte glucose uptake and proinflammatory cytokine expression [PMID:36629908]. In stromal and tumor settings TIMP-1 is itself a transcriptional output of TGF-β/SMAD3, NF-κB, ERK1/2, and STAT1/3 signaling, integrating it into reciprocal tumor–stroma crosstalk [PMID:35787446, PMID:21903858, PMID:11918744, PMID:15451430].","teleology":[{"year":1996,"claim":"Establishing the kinetic mechanism of TIMP-1 inhibition defined how it neutralizes collagenase, answering whether inhibition was simple competitive blockade or a multi-step process.","evidence":"Reconstituted enzyme kinetics with nonlinear regression and C-terminal-truncated mini-collagenase","pmids":["8798626"],"confidence":"High","gaps":["Does not address inhibition of other MMP family members","Structural basis of the slow tight-binding transition not resolved"]},{"year":2000,"claim":"Demonstrating sub-nanomolar inhibition of ADAM-10 but not TACE extended TIMP-1's target range beyond classical MMPs and defined selectivity among sheddases.","evidence":"In vitro quenched fluorescent substrate assay with recombinant catalytic domains","pmids":["10818225"],"confidence":"High","gaps":["Cellular consequences of ADAM-10 inhibition not tested here","No structural model of the TIMP-1/ADAM-10 complex"]},{"year":2004,"claim":"Dissecting TIMP-1's effect on endothelial migration into MMP-dependent and MMP-independent arms first signaled that TIMP-1 has signaling functions separable from protease inhibition.","evidence":"Parallel recombinant TIMP-1 and synthetic MMP inhibitor treatment with FAK/PTEN/paxillin readouts","pmids":["15530852"],"confidence":"Medium","gaps":["Receptor mediating the MMP-independent arm not identified","PTEN induction mechanism unresolved"]},{"year":2005,"claim":"Reciprocal mouse genetics placed TIMP-1 upstream of HGF/Met/p38 in liver regeneration, showing protease inhibition controls growth factor availability and cell-cycle timing.","evidence":"Timp-1 knockout and transgenic overexpression mice with cell-cycle and phospho-Met readouts","pmids":["15726641"],"confidence":"High","gaps":["Which MMP generates active HGF in vivo not pinpointed","Does not separate inhibitory from signaling contributions"]},{"year":2008,"claim":"Identifying the surface proMMP-9/CD44 complex as the platform for TIMP-1 anti-apoptotic signaling provided the first defined receptor context for its survival activity.","evidence":"Co-IP, proMMP-9 siRNA, MMP-9 blocking antibodies, and survival assays in UT-7 cells","pmids":["19010442"],"confidence":"High","gaps":["How the ternary complex transduces signal across the membrane unclear","Generalizability beyond erythroid cells untested here"]},{"year":2011,"claim":"Two studies linked TIMP-1 to ADAM-10/Met regulation in tumors and to NF-κB-driven anti-apoptotic CD63/Akt signaling, connecting protease inhibition and receptor signaling to cancer cell behavior.","evidence":"siRNA knockdown of Timp-1/Adam-10 in liver metastasis model and BRAF/NF-κB epistasis in thyroid carcinoma cells","pmids":["21789719","21903858"],"confidence":"Medium","gaps":["Direct CD63 binding not structurally mapped in these studies","Single-lab pathway placements"]},{"year":2013,"claim":"Multiple studies established that thrombin/STAT1/3, ERK1/2, and NF-κB drive TIMP-1 transcription, and that TIMP-1 governs Reelin processing, topoisomerase phosphorylation, BBB integrity, and CAF expansion, broadening its functional reach.","evidence":"EMSA/antisense (STAT), SILAC phosphoproteomics, organotypic epilepsy and ALF models, in vivo CAF assays","pmids":["11918744","23909892","23493620","23532086","24143225"],"confidence":"Medium","gaps":["Kinase assignments in topoisomerase study are computational","Receptor identity in several contexts not established"]},{"year":2014,"claim":"CD63 was directly defined as the TIMP-1 receptor driving EMT via TWIST1 and, with β1-integrin, Akt/FAK-dependent migration, anchoring the signaling model with domain mutants proving MMP-independence.","evidence":"TIMP-1 overexpression, TWIST1 RNAi rescue, structural MMP-domain mutants, CD63 shRNA, β1-integrin blockade in MCF10A and hNSCs","pmids":["24895412","24635319"],"confidence":"High","gaps":["Stoichiometry of CD63/β1-integrin co-receptor complex unresolved","Proximal signaling step downstream of CD63 not defined"]},{"year":2015,"claim":"Domain-dissecting variants combined with CD63 knockout proved that the CD63-binding signaling domain alone drives granulopoiesis, while Bcl-2 interaction and p90RSK/BAD signaling explain MMP-independent apoptosis suppression.","evidence":"CD63 knockout mice, TIMP-1 functional domain variants, BrdU labeling, T2G mutant and Bcl-2 Co-IP, plus TGF-β/CD63/FAK crosstalk in HCC","pmids":["26001794","26366732","26549110"],"confidence":"High","gaps":["How CD63 couples to JAK2/Akt versus FAK in different cells unresolved","Direct vs indirect nature of TIMP-1/Bcl-2 interaction not structurally defined"]},{"year":2017,"claim":"CD82 was identified as a distinct N-terminal-binding partner mediating TIMP-1 endocytosis and anti-migration, expanding the receptor repertoire beyond CD63.","evidence":"Co-IP, domain mapping, CD82 siRNA, endocytosis and migration assays in pancreatic carcinoma cells","pmids":["28030805"],"confidence":"Medium","gaps":["Relationship between CD82 and CD63 receptor usage unclear","Single-lab finding without reciprocal in vivo validation"]},{"year":2018,"claim":"TIMP-1/CD63 physical interaction was directly confirmed in glioblastoma tissue and shown to couple CD63/β1-integrin to Akt/β-catenin in oligodendrocyte differentiation, reinforcing the receptor model and tying it to Wnt signaling.","evidence":"Proximity ligation assay and Co-IP in glioblastoma; pathway inhibitor and receptor-blocking analysis in OPCs","pmids":["29523123","30121936"],"confidence":"Medium","gaps":["Mechanism linking CD63 to β-catenin not detailed","Crosstalk with canonical Wnt only partially defined"]},{"year":2019,"claim":"Studies tied TIMP-1/CD63/ITGB1/FAK to pathogen-induced dendritic cell hypermotility and TIMP-1/Wnt/β-catenin to MSC osteogenesis, demonstrating context-dependent suppression or promotion of cell behavior.","evidence":"shRNA of TIMP-1/CD63/ITGB1 with FAK/SRC/PI3K inhibitors in DCs; reciprocal TIMP-1 gain/loss with Wnt epistasis in hBMSCs","pmids":["30635444","30473539"],"confidence":"High","gaps":["How identical CD63/FAK axis yields opposite migratory outcomes unresolved","Direct receptor for Wnt/β-catenin effect in MSCs not mapped"]},{"year":2023,"claim":"Discovery of APP/APLP2 as C-terminal-domain TIMP-1 receptors and of ADAMTS-7 as a protease that degrades TIMP-1 added a new signaling axis and a regulatory mechanism controlling TIMP-1 abundance.","evidence":"Unbiased ligand-receptor capture, pull-down, confocal and domain variants (APP); Co-IP, in vitro degradation, FRET, and double-KO mice (ADAMTS-7)","pmids":["36629908","37675562"],"confidence":"High","gaps":["Downstream signaling from APP/TIMP-1 engagement beyond glucose uptake/cytokines undefined","Physiological breadth of ADAMTS-7-mediated TIMP-1 turnover beyond plaques unknown"]},{"year":null,"claim":"How a single CD63-centered receptor system selects between Akt, FAK, ERK, and Wnt outputs to produce opposing context-specific phenotypes, and how the protease-inhibitory and cytokine-like functions are coordinated in vivo, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of TIMP-1/CD63/co-receptor signaling complex","Determinants of pro- versus anti-migratory and pro- versus anti-proliferative outcomes unknown","Integration of inhibitory and signaling roles in physiology not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,2,4,28]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,30]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[3,5,6,7,14]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[3,6,7,12,21]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,3,19,29]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,6,21,22,27]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[1,15,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,6,7,11,12]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[17,24,27]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,12,14]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,23]}],"complexes":["TIMP-1/proMMP-9/CD44 ternary complex","CD63/β1-integrin receptor complex"],"partners":["CD63","ITGB1","MMP9","CD44","CD82","APP","APLP2","ADAMTS7"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P01033","full_name":"Metalloproteinase inhibitor 1","aliases":["Erythroid-potentiating activity","EPA","Fibroblast collagenase inhibitor","Collagenase inhibitor","Tissue inhibitor of metalloproteinases 1","TIMP-1"],"length_aa":207,"mass_kda":23.2,"function":"Metalloproteinase inhibitor that functions by forming one to one complexes with target metalloproteinases, such as collagenases, and irreversibly inactivates them by binding to their catalytic zinc cofactor. Acts on MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13 and MMP16. Does not act on MMP14. Also functions as a growth factor that regulates cell differentiation, migration and cell death and activates cellular signaling cascades via CD63 and ITGB1. Plays a role in integrin signaling. Mediates erythropoiesis in vitro; but, unlike IL3, it is species-specific, stimulating the growth and differentiation of only human and murine erythroid progenitors","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P01033/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TIMP1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TIMP1","total_profiled":1310},"omim":[{"mim_id":"607948","title":"MYCOBACTERIUM TUBERCULOSIS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/607948"},{"mim_id":"606542","title":"HISTONE DEACETYLASE 7A; HDAC7A","url":"https://www.omim.org/entry/606542"},{"mim_id":"605441","title":"ADIPOCYTE-, C1q-, AND COLLAGEN DOMAIN-CONTAINING; ADIPOQ","url":"https://www.omim.org/entry/605441"},{"mim_id":"603308","title":"CATHEPSIN V; CTSV","url":"https://www.omim.org/entry/603308"},{"mim_id":"603030","title":"TOLL-LIKE RECEPTOR 4; TLR4","url":"https://www.omim.org/entry/603030"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"blood vessel","ntpm":2942.8}],"url":"https://www.proteinatlas.org/search/TIMP1"},"hgnc":{"alias_symbol":["EPO"],"prev_symbol":["TIMP","CLGI"]},"alphafold":{"accession":"P01033","domains":[{"cath_id":"2.40.50.120","chopping":"30-200","consensus_level":"medium","plddt":93.5019,"start":30,"end":200}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01033","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01033-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01033-F1-predicted_aligned_error_v6.png","plddt_mean":89.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TIMP1","jax_strain_url":"https://www.jax.org/strain/search?query=TIMP1"},"sequence":{"accession":"P01033","fasta_url":"https://rest.uniprot.org/uniprotkb/P01033.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01033/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01033"}},"corpus_meta":[{"pmid":"10956632","id":"PMC_10956632","title":"TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?","date":"2000","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10956632","citation_count":335,"is_preprint":false},{"pmid":"10818225","id":"PMC_10818225","title":"The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10818225","citation_count":334,"is_preprint":false},{"pmid":"23982756","id":"PMC_23982756","title":"Cytokine functions of TIMP-1.","date":"2013","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/23982756","citation_count":247,"is_preprint":false},{"pmid":"8776359","id":"PMC_8776359","title":"Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds.","date":"1996","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8776359","citation_count":177,"is_preprint":false},{"pmid":"20507371","id":"PMC_20507371","title":"Salivary MMP-8, TIMP-1, and ICTP as markers of advanced periodontitis.","date":"2010","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/20507371","citation_count":153,"is_preprint":false},{"pmid":"15726641","id":"PMC_15726641","title":"Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration.","date":"2005","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15726641","citation_count":120,"is_preprint":false},{"pmid":"24143225","id":"PMC_24143225","title":"TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24143225","citation_count":106,"is_preprint":false},{"pmid":"1639268","id":"PMC_1639268","title":"Differential regulation of TIMP-1 and TIMP-2 mRNA expression in normal and Ha-ras-transformed murine fibroblasts.","date":"1992","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/1639268","citation_count":100,"is_preprint":false},{"pmid":"17569872","id":"PMC_17569872","title":"Role of TIMP-1 and TIMP-2 in the progression of cerebral aneurysms.","date":"2007","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/17569872","citation_count":99,"is_preprint":false},{"pmid":"15144129","id":"PMC_15144129","title":"MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis.","date":"2004","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/15144129","citation_count":87,"is_preprint":false},{"pmid":"15530852","id":"PMC_15530852","title":"TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms.","date":"2004","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15530852","citation_count":86,"is_preprint":false},{"pmid":"11792150","id":"PMC_11792150","title":"TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis.","date":"2002","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/11792150","citation_count":85,"is_preprint":false},{"pmid":"36163148","id":"PMC_36163148","title":"Cut loose TIMP-1: an emerging cytokine in inflammation.","date":"2022","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36163148","citation_count":81,"is_preprint":false},{"pmid":"8322893","id":"PMC_8322893","title":"Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA.","date":"1993","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/8322893","citation_count":78,"is_preprint":false},{"pmid":"12147614","id":"PMC_12147614","title":"Modulation of matrix metalloproteinase and TIMP-1 expression by cytokines in human RPE cells.","date":"2002","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/12147614","citation_count":78,"is_preprint":false},{"pmid":"11502611","id":"PMC_11502611","title":"Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.","date":"2001","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/11502611","citation_count":75,"is_preprint":false},{"pmid":"11437402","id":"PMC_11437402","title":"Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas.","date":"2001","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11437402","citation_count":73,"is_preprint":false},{"pmid":"9543631","id":"PMC_9543631","title":"Localization of TIMP-1, TIMP-2, TIMP-3, gelatinase A and gelatinase B in pathological human corneas.","date":"1998","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/9543631","citation_count":72,"is_preprint":false},{"pmid":"12032189","id":"PMC_12032189","title":"Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease.","date":"2002","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/12032189","citation_count":71,"is_preprint":false},{"pmid":"15781325","id":"PMC_15781325","title":"Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression.","date":"2005","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/15781325","citation_count":70,"is_preprint":false},{"pmid":"12506073","id":"PMC_12506073","title":"Effects of Th2 cytokines on expression of collagen, MMP-1, and TIMP-1 in conjunctival fibroblasts.","date":"2003","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/12506073","citation_count":69,"is_preprint":false},{"pmid":"7960227","id":"PMC_7960227","title":"Expression of stromelysin-1 and TIMP-1 in the involuting mammary gland and in early invasive tumors of the mouse.","date":"1994","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7960227","citation_count":66,"is_preprint":false},{"pmid":"21903858","id":"PMC_21903858","title":"BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.","date":"2011","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21903858","citation_count":65,"is_preprint":false},{"pmid":"19524176","id":"PMC_19524176","title":"Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment.","date":"2008","source":"European journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19524176","citation_count":65,"is_preprint":false},{"pmid":"17047657","id":"PMC_17047657","title":"TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17047657","citation_count":62,"is_preprint":false},{"pmid":"21641958","id":"PMC_21641958","title":"Localization of MMP-2, MMP-9, TIMP-1, and TIMP-2 in human coronal dentine.","date":"2011","source":"Journal of dentistry","url":"https://pubmed.ncbi.nlm.nih.gov/21641958","citation_count":62,"is_preprint":false},{"pmid":"24895412","id":"PMC_24895412","title":"TIMP-1 via TWIST1 induces EMT phenotypes in human breast epithelial cells.","date":"2014","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/24895412","citation_count":62,"is_preprint":false},{"pmid":"8485170","id":"PMC_8485170","title":"Inhibition of stimulated bone resorption in vitro by TIMP-1 and TIMP-2.","date":"1993","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8485170","citation_count":61,"is_preprint":false},{"pmid":"8608981","id":"PMC_8608981","title":"Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer.","date":"1996","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8608981","citation_count":61,"is_preprint":false},{"pmid":"26549110","id":"PMC_26549110","title":"TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate and cancer cells via FAK signaling.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26549110","citation_count":59,"is_preprint":false},{"pmid":"14871825","id":"PMC_14871825","title":"TIMP-1 alters susceptibility to carcinogenesis.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14871825","citation_count":58,"is_preprint":false},{"pmid":"25137018","id":"PMC_25137018","title":"Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.","date":"2014","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25137018","citation_count":58,"is_preprint":false},{"pmid":"12631082","id":"PMC_12631082","title":"Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cells.","date":"2003","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/12631082","citation_count":56,"is_preprint":false},{"pmid":"20207965","id":"PMC_20207965","title":"Effect of TIMP-1 and MMP in pterygium invasion.","date":"2010","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/20207965","citation_count":56,"is_preprint":false},{"pmid":"28386095","id":"PMC_28386095","title":"TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28386095","citation_count":52,"is_preprint":false},{"pmid":"17716308","id":"PMC_17716308","title":"MMP-13 and TIMP-1 determinations in progressive chronic periodontitis.","date":"2007","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/17716308","citation_count":52,"is_preprint":false},{"pmid":"8410600","id":"PMC_8410600","title":"Expression of TIMP-1, TIMP-2 and collagenase mRNA in periodontitis-affected human gingival tissue.","date":"1993","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/8410600","citation_count":51,"is_preprint":false},{"pmid":"26645981","id":"PMC_26645981","title":"Differential effects of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 on atherosclerosis and monocyte/macrophage invasion.","date":"2015","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/26645981","citation_count":49,"is_preprint":false},{"pmid":"26001794","id":"PMC_26001794","title":"TIMP-1 signaling via CD63 triggers granulopoiesis and neutrophilia in mice.","date":"2015","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/26001794","citation_count":47,"is_preprint":false},{"pmid":"21789719","id":"PMC_21789719","title":"Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10.","date":"2011","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/21789719","citation_count":47,"is_preprint":false},{"pmid":"24876280","id":"PMC_24876280","title":"MMP-2, MMP-3, TIMP-1, TIMP-2, and TIMP-3 protein levels in human aqueous humor: relationship with axial length.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24876280","citation_count":46,"is_preprint":false},{"pmid":"37675562","id":"PMC_37675562","title":"ADAMTS-7 Modulates Atherosclerotic Plaque Formation by Degradation of TIMP-1.","date":"2023","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/37675562","citation_count":45,"is_preprint":false},{"pmid":"15451430","id":"PMC_15451430","title":"Pancreatic cancer stimulates pancreatic stellate cell proliferation and TIMP-1 production through the MAP kinase pathway.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15451430","citation_count":45,"is_preprint":false},{"pmid":"24635319","id":"PMC_24635319","title":"TIMP-1 modulates chemotaxis of human neural stem cells through CD63 and integrin signalling.","date":"2014","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/24635319","citation_count":44,"is_preprint":false},{"pmid":"10232461","id":"PMC_10232461","title":"Timp-1, -2 and -3 show coexpression with gelatinases A and B during mouse tooth morphogenesis.","date":"1999","source":"European journal of oral sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10232461","citation_count":42,"is_preprint":false},{"pmid":"19383344","id":"PMC_19383344","title":"TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles.","date":"2008","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19383344","citation_count":42,"is_preprint":false},{"pmid":"19010442","id":"PMC_19010442","title":"TIMP-1 binding to proMMP-9/CD44 complex localized at the cell surface promotes erythroid cell survival.","date":"2008","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19010442","citation_count":41,"is_preprint":false},{"pmid":"30121936","id":"PMC_30121936","title":"TIMP-1 Promotes Oligodendrocyte Differentiation Through Receptor-Mediated Signaling.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30121936","citation_count":40,"is_preprint":false},{"pmid":"23834019","id":"PMC_23834019","title":"Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review.","date":"2013","source":"Scandinavian journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/23834019","citation_count":40,"is_preprint":false},{"pmid":"23532086","id":"PMC_23532086","title":"TIMP-1 attenuates blood-brain barrier permeability in mice with acute liver failure.","date":"2013","source":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23532086","citation_count":40,"is_preprint":false},{"pmid":"14695775","id":"PMC_14695775","title":"Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis.","date":"2004","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/14695775","citation_count":39,"is_preprint":false},{"pmid":"22407827","id":"PMC_22407827","title":"TIMP-1 deficiency leads to lethal partial hepatic ischemia and reperfusion injury.","date":"2012","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22407827","citation_count":39,"is_preprint":false},{"pmid":"35787446","id":"PMC_35787446","title":"Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma.","date":"2022","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35787446","citation_count":37,"is_preprint":false},{"pmid":"25756591","id":"PMC_25756591","title":"TIMP-1 overexpression in lung carcinoma enhances tumor kinetics and angiogenesis in brain metastasis.","date":"2015","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25756591","citation_count":37,"is_preprint":false},{"pmid":"23909892","id":"PMC_23909892","title":"TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells.","date":"2013","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/23909892","citation_count":35,"is_preprint":false},{"pmid":"16718785","id":"PMC_16718785","title":"Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models.","date":"2006","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16718785","citation_count":35,"is_preprint":false},{"pmid":"30635444","id":"PMC_30635444","title":"TIMP-1 promotes hypermigration of Toxoplasma-infected primary dendritic cells via CD63-ITGB1-FAK signaling.","date":"2019","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/30635444","citation_count":35,"is_preprint":false},{"pmid":"8798626","id":"PMC_8798626","title":"The mechanism of inhibition of collagenase by TIMP-1.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8798626","citation_count":35,"is_preprint":false},{"pmid":"17706812","id":"PMC_17706812","title":"Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI.","date":"2007","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17706812","citation_count":35,"is_preprint":false},{"pmid":"22769410","id":"PMC_22769410","title":"The immunohistochemical characterization of MMP-2, MMP-10, TIMP-1, TIMP-2, and podoplanin in oral squamous cell carcinoma.","date":"2012","source":"Oral surgery, oral medicine, oral pathology and oral radiology","url":"https://pubmed.ncbi.nlm.nih.gov/22769410","citation_count":34,"is_preprint":false},{"pmid":"12454040","id":"PMC_12454040","title":"Latanoprost's effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cells.","date":"2002","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/12454040","citation_count":33,"is_preprint":false},{"pmid":"12586482","id":"PMC_12586482","title":"Synovial MMP-3 and TIMP-1 levels and their correlation with cytokine expression in canine rheumatoid arthritis.","date":"2003","source":"Veterinary immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/12586482","citation_count":33,"is_preprint":false},{"pmid":"26366732","id":"PMC_26366732","title":"TIMP-1 Inhibits Apoptosis in Lung Adenocarcinoma Cells via Interaction with Bcl-2.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26366732","citation_count":33,"is_preprint":false},{"pmid":"20578063","id":"PMC_20578063","title":"Epidermal growth factor (EGF) induces motility and upregulates MMP-9 and TIMP-1 in bovine trophoblast cells.","date":"2010","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/20578063","citation_count":33,"is_preprint":false},{"pmid":"23493620","id":"PMC_23493620","title":"TIMP-1 inhibits the proteolytic processing of Reelin in experimental epilepsy.","date":"2013","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/23493620","citation_count":33,"is_preprint":false},{"pmid":"32961536","id":"PMC_32961536","title":"The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.","date":"2020","source":"Digestive diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/32961536","citation_count":31,"is_preprint":false},{"pmid":"29523123","id":"PMC_29523123","title":"Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.","date":"2018","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29523123","citation_count":30,"is_preprint":false},{"pmid":"17847032","id":"PMC_17847032","title":"Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer.","date":"2008","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17847032","citation_count":29,"is_preprint":false},{"pmid":"22754717","id":"PMC_22754717","title":"Expression and Roles of MMP-2, MMP-9, MMP-13, TIMP-1, and TIMP-2 in Allergic Nasal Mucosa.","date":"2012","source":"Allergy, asthma & immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/22754717","citation_count":29,"is_preprint":false},{"pmid":"25009588","id":"PMC_25009588","title":"Effect of osteopontin on TIMP-1 and TIMP-2 mRNA in chondrocytes of human knee osteoarthritis in vitro.","date":"2014","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25009588","citation_count":28,"is_preprint":false},{"pmid":"33942633","id":"PMC_33942633","title":"Diagnostic values of MMP-7, MMP-9, MMP-11, TIMP-1, TIMP-2, CEA, and CA19-9 in patients with colorectal cancer.","date":"2021","source":"The Journal of international medical research","url":"https://pubmed.ncbi.nlm.nih.gov/33942633","citation_count":28,"is_preprint":false},{"pmid":"30473539","id":"PMC_30473539","title":"TIMP-1 inhibits proliferation and osteogenic differentiation of hBMSCs through Wnt/β-catenin signaling.","date":"2019","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/30473539","citation_count":26,"is_preprint":false},{"pmid":"36629908","id":"PMC_36629908","title":"TIMP-1 is a novel ligand of Amyloid Precursor Protein and triggers a proinflammatory phenotype in human monocytes.","date":"2023","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/36629908","citation_count":26,"is_preprint":false},{"pmid":"29845213","id":"PMC_29845213","title":"Involvement of TIMP-1 in PECAM-1-mediated tumor dissemination.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29845213","citation_count":26,"is_preprint":false},{"pmid":"24526442","id":"PMC_24526442","title":"Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 expression in murine experimental retinal detachment.","date":"2014","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/24526442","citation_count":26,"is_preprint":false},{"pmid":"22469989","id":"PMC_22469989","title":"Expression of STAT3, MMP-1 and TIMP-1 in gastric cancer and correlation with pathological features.","date":"2012","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/22469989","citation_count":26,"is_preprint":false},{"pmid":"37700105","id":"PMC_37700105","title":"TIMP-1 Protects Tight Junctions of Brain Endothelial Cells From MMP-Mediated Degradation.","date":"2023","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/37700105","citation_count":24,"is_preprint":false},{"pmid":"16261161","id":"PMC_16261161","title":"GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16261161","citation_count":23,"is_preprint":false},{"pmid":"34557330","id":"PMC_34557330","title":"The role of matrix metalloproteinase-9 and its inhibitor TIMP-1 in burn injury: a systematic review.","date":"2021","source":"International journal of burns and trauma","url":"https://pubmed.ncbi.nlm.nih.gov/34557330","citation_count":22,"is_preprint":false},{"pmid":"30167842","id":"PMC_30167842","title":"TIMP-1 Promotes the Immune Response in Influenza-Induced Acute Lung Injury.","date":"2018","source":"Lung","url":"https://pubmed.ncbi.nlm.nih.gov/30167842","citation_count":22,"is_preprint":false},{"pmid":"30035371","id":"PMC_30035371","title":"TFF1 antagonizes TIMP-1 mediated proliferative functions in gastric cancer.","date":"2018","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30035371","citation_count":21,"is_preprint":false},{"pmid":"9822966","id":"PMC_9822966","title":"TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid.","date":"1998","source":"Japanese journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/9822966","citation_count":21,"is_preprint":false},{"pmid":"31861382","id":"PMC_31861382","title":"TIMP-1 is Overexpressed and Secreted by Platinum Resistant Epithelial Ovarian Cancer Cells.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31861382","citation_count":20,"is_preprint":false},{"pmid":"28197741","id":"PMC_28197741","title":"Correlation between the COL4A3, MMP-9, and TIMP-1 polymorphisms and risk of keratoconus.","date":"2017","source":"Japanese journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/28197741","citation_count":20,"is_preprint":false},{"pmid":"11918744","id":"PMC_11918744","title":"STAT1 and STAT3 mediate thrombin-induced expression of TIMP-1 in human glomerular mesangial cells.","date":"2002","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/11918744","citation_count":20,"is_preprint":false},{"pmid":"28510611","id":"PMC_28510611","title":"MMP-10, MMP-7, TIMP-1 and TIMP-2 mRNA expression in esophageal cancer.","date":"2017","source":"Acta biochimica Polonica","url":"https://pubmed.ncbi.nlm.nih.gov/28510611","citation_count":19,"is_preprint":false},{"pmid":"23841813","id":"PMC_23841813","title":"TIMP-1 polymorphisms in a Chinese Han population with intracerebral hemorrhage.","date":"2013","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23841813","citation_count":19,"is_preprint":false},{"pmid":"29938527","id":"PMC_29938527","title":"Effects of Controlling Abnormal Joint Movement on Expression of MMP13 and TIMP-1 in Osteoarthritis.","date":"2018","source":"Cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/29938527","citation_count":18,"is_preprint":false},{"pmid":"9758100","id":"PMC_9758100","title":"Equine TIMP-1 and TIMP-2: identification, activity and cellular sources.","date":"1998","source":"Equine veterinary journal","url":"https://pubmed.ncbi.nlm.nih.gov/9758100","citation_count":18,"is_preprint":false},{"pmid":"31258700","id":"PMC_31258700","title":"MMP-9 and TIMP-1 in placenta of hypertensive disorder complicating pregnancy.","date":"2019","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31258700","citation_count":18,"is_preprint":false},{"pmid":"35625637","id":"PMC_35625637","title":"Increase in Serum MMP-9 and TIMP-1 Concentrations during Alcohol Intoxication in Adolescents-A Preliminary Study.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/35625637","citation_count":18,"is_preprint":false},{"pmid":"28030805","id":"PMC_28030805","title":"TIMP-1 and CD82, a promising combined evaluation marker for PDAC.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28030805","citation_count":17,"is_preprint":false},{"pmid":"17695477","id":"PMC_17695477","title":"Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer.","date":"2007","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17695477","citation_count":17,"is_preprint":false},{"pmid":"10575588","id":"PMC_10575588","title":"Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) stimulate osteoclastic bone resorption.","date":"1999","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10575588","citation_count":17,"is_preprint":false},{"pmid":"23943285","id":"PMC_23943285","title":"Identification of miR-1293 potential target gene: TIMP-1.","date":"2013","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23943285","citation_count":17,"is_preprint":false},{"pmid":"10502306","id":"PMC_10502306","title":"Increased TIMP-1 activity results in increased expression of gelatinases and altered cell motility.","date":"1999","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10502306","citation_count":17,"is_preprint":false},{"pmid":"29989318","id":"PMC_29989318","title":"TIMP-1 association with collagen type I overproduction in hereditary gingival fibromatosis.","date":"2018","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/29989318","citation_count":17,"is_preprint":false},{"pmid":"27486337","id":"PMC_27486337","title":"Evaluation of MMP-9 and MMP-2 and their suppressor TIMP-1 and TIMP-2 in adenocarcinoma of esophagogastric junction.","date":"2016","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/27486337","citation_count":17,"is_preprint":false},{"pmid":"22472034","id":"PMC_22472034","title":"Expression of MMPs and TIMP-1 in smoker and nonsmoker chronic periodontitis patients before and after periodontal treatment.","date":"2012","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/22472034","citation_count":17,"is_preprint":false},{"pmid":"21763297","id":"PMC_21763297","title":"Combinatorial effect of TIMP-1 and α1AT gene polymorphisms on development of chronic obstructive pulmonary disease.","date":"2011","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21763297","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54100,"output_tokens":8597,"usd":0.145627,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18701,"output_tokens":5075,"usd":0.11019,"stage2_stop_reason":"end_turn"},"total_usd":0.255817,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"TIMP-1 inhibits the catalytic activity of ADAM-10 with an apparent inhibition constant of approximately 0.1 nM, as measured by a quenched fluorescent substrate assay, distinguishing ADAM-10 inhibition from TACE (which is only inhibited by TIMP-3).\",\n      \"method\": \"In vitro enzyme inhibition assay (quenched fluorescent substrate assay) with recombinant proteins\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro biochemical assay with recombinant catalytic domain and quantified Ki, single lab but rigorous enzyme kinetics\",\n      \"pmids\": [\"10818225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TIMP-1 is a slow, tight-binding inhibitor of fibroblast-type collagenase (MMP-1) operating via a noncompetitive two-step mechanism: rapid formation of a reversible complex (Kd ~8 nM) followed by slow formation of a tight complex (global Kd ~0.1 nM). The C-terminal domain of collagenase is required for the initial rapid binding step.\",\n      \"method\": \"Enzyme kinetics — time-course inhibition assays analyzed by nonlinear regression and numerical integration; comparison with C-terminal domain-truncated 'mini-collagenase'\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted in vitro kinetic analysis with multiple analytical methods, truncation mutant validation\",\n      \"pmids\": [\"8798626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TIMP-1 negatively regulates hepatocyte growth factor (HGF) activity during liver regeneration: TIMP-1 loss-of-function in Timp-1−/− mice elevated MMP activity and increased active HGF, leading to enhanced phosphorylation of Met and its downstream effector p38, accelerating hepatocyte cell cycle progression (earlier cyclin D1, PCNA, phospho-histone H3). Conversely, TIMP-1 gain-of-function delayed cell cycle progression.\",\n      \"method\": \"Genetic loss-of-function (Timp-1−/− mice) and gain-of-function (transgenic overexpression); real-time RT-PCR; immunostaining for cell cycle markers and phospho-Met\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain- and loss-of-function genetic models with multiple orthogonal cell-cycle readouts and pathway (HGF/Met/p38) placement\",\n      \"pmids\": [\"15726641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"TIMP-1 binds specifically to proMMP-9 at the cell surface, where proMMP-9 is anchored to the plasma membrane via CD44. Formation of this ternary TIMP-1/proMMP-9/CD44 complex is necessary for TIMP-1-induced anti-apoptotic signaling (JAK2/PI3K/Akt pathway) in UT-7 erythroid cells; silencing proMMP-9 abrogated the TIMP-1 survival effect, and MMP-9-function-blocking antibodies that prevent TIMP-1 binding also abolished cell survival without reproducing the effect themselves.\",\n      \"method\": \"Co-immunoprecipitation, proMMP-9 siRNA knockdown, MMP-9 function-blocking antibodies, synthetic MMP inhibitor, cell survival assays\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, multiple knockdown/blocking approaches, clear mechanistic pathway placement, single lab\",\n      \"pmids\": [\"19010442\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Tumor cell-derived TIMP-1 maintains Met receptor signaling by inhibiting ADAM-10-mediated shedding of Met; knockdown of tumor-cell Timp-1 suppressed Met phosphorylation and HGF-induced Met activation, whereas knockdown of ADAM-10 mimicked Timp-1 overexpression by increasing Met phosphorylation and tumor cell scattering in the liver.\",\n      \"method\": \"siRNA knockdown of Timp-1 and Adam-10 in syngeneic murine experimental liver metastasis model; in vitro Met phosphorylation assays; immunolocalization in metastatic foci\",\n      \"journal\": \"Clinical & experimental metastasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo knockdown with in vitro mechanistic validation, parallel Adam-10 knockdown epistasis, single lab\",\n      \"pmids\": [\"21789719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 binding to its surface receptor CD63 activates intracellular signaling that induces EMT in human breast epithelial MCF10A cells, evidenced by loss of E-cadherin and gain of vimentin, N-cadherin, and fibronectin, through upregulation of the transcription factor TWIST1; RNAi knockdown of TWIST1 rescued E-cadherin expression. This function is independent of TIMP-1's MMP-inhibitory domain, as demonstrated with structural TIMP-1 mutants.\",\n      \"method\": \"TIMP-1 overexpression, RNAi knockdown of TWIST1, structural MMP-inhibitory domain mutants, immunofluorescence for EMT markers\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue (TWIST1 knockdown restores E-cadherin), domain mutant establishes MMP-independence, multiple orthogonal markers, single lab\",\n      \"pmids\": [\"24895412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TIMP-1 signals through CD63 to activate β1-integrin-mediated Akt and FAK phosphorylation, promoting adhesion and chemotaxis of human neural stem cells (hNSCs); shRNA silencing of CD63 or blocking of β1-integrin abrogated the TIMP-1-induced migration, focal adhesion formation, and cytoskeletal reorganization.\",\n      \"method\": \"shRNA knockdown of CD63, β1-integrin blocking antibody, PI3K inhibitor, migration assays, immunofluorescence for focal adhesions and F-actin\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological dissection of CD63/β1-integrin/Akt/FAK signaling axis, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"24635319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP-1 triggers granulopoiesis and neutrophilia via CD63-mediated signaling: elevated systemic TIMP-1 increased myeloid progenitor proliferation (BrdU incorporation) and granulopoiesis gene expression in bone marrow. TIMP-1 variants with intact CD63-binding (signaling) domain but lacking MMP-inhibitory activity were sufficient to induce neutrophilia, and genetic ablation of CD63 abolished both TIMP-1-induced neutrophilia and granulopoiesis.\",\n      \"method\": \"In vivo TIMP-1 elevation in mice; BrdU pulse-labeling; TIMP-1 functional domain variants; CD63 knockout mice\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain-dissecting TIMP-1 variants combined with CD63 knockout, BrdU proliferation assay, clear in vivo phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"26001794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP-1 mediates TGF-β-dependent crosstalk between hepatic stellate cells (HSCs) and hepatocellular carcinoma (HCC) cells by activating FAK signaling via interaction with CD63: TGF-β signaling in HSCs increased TIMP-1 secretion, which then activated FAK in HCC cells; this promoted HCC proliferation, motility, and survival.\",\n      \"method\": \"Conditioned medium experiments, TGF-β signaling inhibition (EW-7197), in vivo orthotopic xenograft model, FAK/Akt signaling assessment\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vivo orthotopic model with pharmacological inhibition, mechanistic pathway (TGF-β/TIMP-1/CD63/FAK) placed, single lab, limited genetic dissection of TIMP-1 interaction\",\n      \"pmids\": [\"26549110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BRAF(V600E) mutation in papillary thyroid carcinoma activates NF-κB, which upregulates TIMP-1; TIMP-1 then binds its surface receptor CD63, activating Akt signaling and conferring anti-apoptotic behavior. Silencing BRAF in BCPAP cells (harboring BRAF(V600E)) reduced TIMP-1 expression and NF-κB activity; sorafenib (but not MEK inhibitor) inhibited both NF-κB and TIMP-1/Akt signaling, indicating the pathway is MEK-independent.\",\n      \"method\": \"siRNA knockdown of BRAF, specific pathway inhibitors, luciferase NF-κB reporter, invasion assays, immunohistochemistry in 56 PTC specimens\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown plus pharmacological epistasis, pathway placement (BRAF→NF-κB→TIMP-1→CD63→Akt), single lab\",\n      \"pmids\": [\"21903858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"TIMP-1 inhibits endothelial cell migration through two distinct mechanisms: (1) MMP-dependent pathway involving increased expression and junctional accumulation of VE-cadherin and PECAM-1; (2) MMP-independent pathway involving stimulation of PTEN expression with subsequent dephosphorylation of focal adhesion kinase (FAK, pY397) and paxillin and reduction of F-actin stress fibers and focal adhesions.\",\n      \"method\": \"Recombinant TIMP-1 and synthetic MMP inhibitor treatment; immunofluorescence; Western blot for FAK, paxillin, PTEN, VE-cadherin, PECAM-1\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — parallel use of recombinant TIMP-1 and synthetic MMP inhibitors to dissect MMP-dependent vs independent pathways, multiple protein readouts, single lab\",\n      \"pmids\": [\"15530852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TIMP-1 promotes oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes via a CD63/β1-integrin receptor complex that activates Akt and downstream β-catenin signaling; this trophic action is independent of TIMP-1's MMP-inhibitory function, and was counteracted (but not abolished) by canonical Wnt7a signaling.\",\n      \"method\": \"Pharmacological inhibitors, receptor blocking, signaling pathway analysis (Akt, β-catenin), comparison with MMP-inhibitory function\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — identification of CD63/β1-integrin/Akt/β-catenin pathway, MMP-independence established, single lab with multiple pathway readouts\",\n      \"pmids\": [\"30121936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Toxoplasma gondii-induced TIMP-1 secretion from dendritic cells drives DC hypermotility via a CD63-ITGB1(β1-integrin)-FAK signaling axis; shRNA silencing of TIMP-1, CD63, or ITGB1, and pharmacological inhibition of FAK, SRC, or PI3K each abolished parasite-induced DC hypermotility.\",\n      \"method\": \"shRNA gene silencing of TIMP-1, CD63, ITGB1, FAK; pharmacological antagonism of FAK, SRC, PI3K; DC migration assays\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple independent genetic knockdowns and pharmacological inhibitors converging on TIMP-1→CD63→ITGB1→FAK axis, rigorous controls\",\n      \"pmids\": [\"30635444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 inhibits MMP activity in epileptic conditions, thereby preventing proteolytic processing of Reelin; kainate treatment upregulated TIMP-1 in hippocampal neurons, functional inhibition of TIMP-1 prevented kainate-induced impairment of Reelin cleavage, and application of recombinant TIMP-1 alone was sufficient to impair Reelin processing and induce granule cell dispersion (GCD).\",\n      \"method\": \"Organotypic hippocampal slice cultures, kainate epilepsy model, TIMP-1 functional inhibition, recombinant TIMP-1 application, immunolabeling for TIMP-1 and Reelin processing\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function of TIMP-1 with specific Reelin cleavage readout, single lab\",\n      \"pmids\": [\"23493620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TIMP-1 is a novel ligand for Amyloid Precursor Protein (APP) and APP-like protein 2 (APLP2); TIMP-1 binding to APP on human monocytes triggers glucose uptake and proinflammatory cytokine expression. Mechanistically, TIMP-1 acts via its C-terminal domain and through APP, as demonstrated by recombinant TIMP-1 C-terminal domain variants and in silico docking, and confirmed by unbiased ligand-receptor capture screening, pull-down assays, and confocal microscopy.\",\n      \"method\": \"Unbiased ligand-receptor capture screening, pull-down assays, confocal microscopy, recombinant TIMP-1 domain variants, in silico docking, glucose uptake assay, cytokine expression\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal biochemical methods (pull-down, proximity assay, confocal) plus functional domain dissection, unbiased discovery approach, single lab\",\n      \"pmids\": [\"36629908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ADAMTS-7 degrades TIMP-1 by direct binding via its catalytic domain (demonstrated by co-immunoprecipitation and in vitro degradation assays), thereby reducing TIMP-1's inhibitory capacity toward MMP-9 and increasing collagen degradation in atherosclerotic plaques.\",\n      \"method\": \"Co-immunoprecipitation, in vitro degradation assay, FRET-based protein-protein interaction assay, mass spectrometry of atherosclerotic plaques from Apoe−/−Adamts7−/− vs. Apoe−/− mice, Picrosirius red collagen staining\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro reconstitution of ADAMTS-7-mediated TIMP-1 degradation plus Co-IP binding, multiple orthogonal methods, in vivo validation in double-KO mice\",\n      \"pmids\": [\"37675562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In lung adenocarcinoma, TIMP-1 overexpression in tumor-associated fibroblasts (TAFs) is driven specifically by the TGF-β1/SMAD3 pathway; fibroblast-secreted TIMP-1 enhances growth and invasion of ADC cancer cells in a manner requiring cancer cell surface receptor CD63; SMAD3 or TIMP-1 knockdown in TAFs attenuated tumor aggressiveness in vivo.\",\n      \"method\": \"shRNA/siRNA knockdown of SMAD3, TIMP-1, CD63; co-culture assays; in vivo co-injection xenograft model; gene expression analyses in human ADC vs SCC specimens\",\n      \"journal\": \"Matrix biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic validation with both stromal and cancer cell genetic knockdowns, CD63 dependency established, TGF-β1/SMAD3 pathway mechanistically placed, single lab\",\n      \"pmids\": [\"35787446\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TIMP-1 inhibits apoptosis in lung adenocarcinoma cells via interaction with Bcl-2 (demonstrated by co-immunoprecipitation) and activation of p90RSK with phosphorylation of BAD at serine 112, reducing Bax levels and increasing mitochondrial permeability; this anti-apoptotic function is independent of MMP inhibition (TIMP-1 T2G mutant lacking MMP inhibitory activity retains full anti-apoptotic effect).\",\n      \"method\": \"Co-immunoprecipitation, TIMP-1 T2G structural mutant (MMP-inhibitory domain ablated), Western blot for PARP cleavage/BAD phosphorylation/Bax, staurosporine apoptosis assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — domain-dissecting mutant establishes MMP-independence, Co-IP for TIMP-1/Bcl-2 interaction, downstream pathway (p90RSK/BAD/Bax) validated, single lab\",\n      \"pmids\": [\"26366732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"STAT1 and STAT3 mediate thrombin-induced TIMP-1 gene transcription in human glomerular mesangial cells; thrombin induced STAT-DNA binding activity, and antisense oligonucleotides against STAT1 or STAT3 inhibited both STAT-DNA binding and TIMP-1 mRNA expression; the SIF band on EMSA contained both STAT1 and STAT3.\",\n      \"method\": \"Northern blot, EMSA, supershift assay, antisense oligonucleotides for STAT1 and STAT3\",\n      \"journal\": \"Kidney international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus antisense knockdown with transcriptional readout, supershift confirms STAT proteins, single lab\",\n      \"pmids\": [\"11918744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Recombinant TIMP-1 (and TIMP-2) inhibit stimulated bone resorption (induced by PTH or 1,25-dihydroxyvitamin D3) in cultured neonatal mouse calvariae in a dose-dependent, reversible manner, with complete inhibition at 1 μg/ml; neither TIMP affected protein synthesis, DNA synthesis, or PTH-enhanced β-glucuronidase secretion, suggesting the inhibitory effect is targeted at matrix metalloproteinase-mediated resorption steps.\",\n      \"method\": \"Recombinant protein treatment in organ culture (calvarial bone resorption assay); dose-response analysis; controls for cell toxicity and PTH signaling\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro organ culture with dose-response and multiple control readouts, single lab, recombinant protein\",\n      \"pmids\": [\"8485170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1-overexpressing cancer cells exhibit increased expression and phosphorylation of topoisomerases 1, 2A, and 2B, which correlates with resistance to topoisomerase inhibitors; pathway analysis implicates protein kinases CK2a, CDK1, PLK1, and ATM in topoisomerase hyperphosphorylation in TIMP-1-high MCF-7 cells.\",\n      \"method\": \"SILAC-based quantitative mass spectrometry of global proteome and phosphoproteome in TIMP-1-high vs. TIMP-1-low MCF-7 cells; NetworKIN kinase prediction\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — quantitative proteomics/phosphoproteomics is orthogonal and unbiased but kinase assignment is computational; single lab\",\n      \"pmids\": [\"23909892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TIMP-1 and CD63 proteins are co-expressed at the cellular level in glioblastoma cells, located in close molecular proximity (demonstrated by proximity ligation assay), and co-immunoprecipitate, confirming a physical protein-protein interaction between TIMP-1 and its surface receptor CD63 in glioblastoma.\",\n      \"method\": \"Proximity ligation assay, co-immunoprecipitation, immunofluorescence co-localization in human glioblastoma tissue\",\n      \"journal\": \"BMC cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal binding assays (Co-IP + PLA) confirming TIMP-1/CD63 interaction in tissue context, single lab\",\n      \"pmids\": [\"29523123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CD82 (KAI1/tetraspanin) is a binding partner of TIMP-1 on the surface of pancreatic adenocarcinoma cells; CD82 binds TIMP-1 via its large extracellular loop interacting with the N-terminal region of TIMP-1, co-localizes with TIMP-1, and facilitates membrane-bound TIMP-1 endocytosis, contributing to the anti-migration effect of TIMP-1; CD82 silencing partially eliminates these functions.\",\n      \"method\": \"Co-immunoprecipitation, co-localization, CD82 siRNA silencing, TIMP-1 endocytosis assay, cell migration assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding shown by Co-IP, domain mapping (N-terminal TIMP-1/EL2 of CD82), genetic knockdown with functional readout, single lab\",\n      \"pmids\": [\"28030805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TIMP-1 inhibits proliferation and osteogenic differentiation of human bone marrow-derived MSCs (hBMSCs) through the Wnt/β-catenin signaling pathway: TIMP-1 knockdown upregulated β-catenin and cyclin D1, enhanced osteogenic markers (Sox9, osteocalcin, RUNX-2), and restored Dickkopf-1-inhibited β-catenin/cyclin D1/RUNX-2 expression; conversely, TIMP-1 overexpression attenuated Wnt3a-induced β-catenin/cyclin D1/RUNX-2 upregulation.\",\n      \"method\": \"Stable TIMP-1 overexpression and knockdown in hBMSCs; Alizarin Red S staining; ALP activity; Western blot for β-catenin, cyclin D1, RUNX-2; Wnt3a and Dickkopf-1 pathway manipulation\",\n      \"journal\": \"Bioscience reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal gain and loss of function with Wnt pathway activator and inhibitor epistasis, multiple osteogenic readouts, single lab\",\n      \"pmids\": [\"30473539\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TIMP-1 gene-deficient fibrosarcoma cells show significantly increased sensitivity to chemotherapy-induced apoptosis compared to genetically identical wild-type cells, demonstrating that endogenous TIMP-1 protects cells from apoptosis independently of exogenous supplementation.\",\n      \"method\": \"TIMP-1 gene-deficient vs. wild-type fibrosarcoma cells derived from mouse lung tissue; chemotherapy-induced apoptosis assays\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — clean genetic comparison (KO vs WT isogenic cells) with defined apoptosis phenotype, single lab, limited pathway placement in this study\",\n      \"pmids\": [\"17047657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 promotes cellular proliferation in gastric cancer in an NF-κB-dependent manner: TNF-α and NF-κB activation induced TIMP-1 expression, NF-κB inhibition (BAY11-7082) downregulated TIMP-1, and TFF1 reconstitution suppressed NF-κB and inhibited TIMP-1-mediated proliferative potential (EDU assay).\",\n      \"method\": \"NF-κB inhibitor BAY11-7082, TFF1 reconstitution with recombinant protein, quantitative RT-PCR, EDU proliferation assay, gastric organoids from Tff1-KO mice\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic manipulation of NF-κB/TIMP-1 axis with functional proliferation readout, confirmed in organoid model, single lab\",\n      \"pmids\": [\"30035371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Pancreatic cancer-conditioned medium stimulates pancreatic stellate cell (PSC) proliferation and TIMP-1 gene expression through the MAP kinase (ERK1/2) pathway; inhibition of ERK1/2 phosphorylation with U0126 prevented both growth and TIMP-1 upregulation.\",\n      \"method\": \"PSC culture with PANC-1 conditioned medium, ERK1/2 inhibitor U0126, real-time PCR for TIMP-1 mRNA, DNA synthesis and cell counting\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway inhibition (ERK1/2) with parallel functional (proliferation) and molecular (TIMP-1 mRNA) readouts, single lab\",\n      \"pmids\": [\"15451430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"GPI-anchored TIMP-1 inserted into the plasma membrane of renal cell carcinoma (RCC) cells altered the association of MMPs with the cell surface, inhibited RCC proliferation, and rendered normally FAS-resistant RCC cells sensitive to FAS-induced apoptosis by shifting the balance of pro- and anti-apoptotic BCL-2-family proteins; perforin-mediated lysis was not affected.\",\n      \"method\": \"GPI-TIMP-1 fusion protein treatment of RCC cell lines; FAS apoptosis assays; perforin lysis assay; BCL-2-family Western blotting\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — engineered TIMP-1-GPI construct to manipulate cell surface MMP balance, separate FAS vs perforin mechanistic dissection, BCL-2 family readout, single lab\",\n      \"pmids\": [\"16261161\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 attenuates blood-brain barrier (BBB) permeability in acute liver failure by inhibiting MMP-9, reducing activation of EGFR and p38 MAPK signaling, and restoring tight junction protein occludin; intracerebroventricular delivery of TIMP-1 cDNA or pegylated TIMP-1 protein provided similar protection.\",\n      \"method\": \"Intracerebroventricular TIMP-1 cDNA injection and pegylated-TIMP-1 protein treatment in murine ALF model; sodium fluorescein permeability assay; EGFR and p38 MAPK Western blot; occludin immunostaining\",\n      \"journal\": \"Journal of cerebral blood flow and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo rescue experiments with two delivery strategies (gene and protein), signaling pathway (EGFR/p38) and tight junction (occludin) readouts, single lab\",\n      \"pmids\": [\"23532086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TIMP-1 promotes cancer associated fibroblast (CAF) accumulation in prostate and colon cancer and enhances CAF proliferation and migration in vitro; TIMP-1 activates ERK1/2 kinase signaling in prostate CAFs.\",\n      \"method\": \"In vivo tumor growth assays with TIMP-1-overexpressing cells; in vitro CAF proliferation/migration assays; Western blot for ERK1/2 phosphorylation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro models with ERK1/2 signaling pathway placement, single lab, limited mechanistic depth\",\n      \"pmids\": [\"24143225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TIMP-1 (and TIMP-2) at nanomolar concentrations stimulate osteoclastic bone resorption in vitro through a mechanism related to the functional activity of osteoclasts (not osteoclast number), which cannot be replicated by synthetic MMP inhibitors, indicating the bone resorption-stimulating activity of TIMP-1 is independent of its MMP-inhibitory effect.\",\n      \"method\": \"Removal/reconstitution of TIMPs from FCS in osteoclast bone resorption cultures; TRAP-positive cell counting; comparison with synthetic metalloproteinase inhibitors BE16627B and R94138\",\n      \"journal\": \"Journal of bone and mineral metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution experiment with recombinant TIMPs and MMP inhibitor controls to dissect mechanism, single lab\",\n      \"pmids\": [\"10575588\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TIMP-1 is a multifunctional secreted glycoprotein that acts both as an endogenous metalloproteinase inhibitor (blocking MMPs and ADAM-10 via tight-binding inhibition, including a two-step noncompetitive mechanism for collagenase) and as a cytokine-like signaling molecule that binds cell-surface receptors—principally CD63 (and its co-receptors β1-integrin, proMMP-9/CD44), as well as Amyloid Precursor Protein and CD82—to activate intracellular pathways including JAK2/PI3K/Akt, FAK, ERK1/2, Wnt/β-catenin, and STAT1/3, thereby regulating cell survival/apoptosis, proliferation, differentiation (oligodendrocytes, osteoblasts), migration, EMT, granulopoiesis, and immune cell activation independently of its MMP-inhibitory domain.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TIMP-1 is a secreted glycoprotein that operates as both an endogenous metalloproteinase inhibitor and a cytokine-like signaling ligand that controls cell survival, proliferation, differentiation, migration, and immune cell activation [#1, #5, #7]. As a protease inhibitor it is a slow, tight-binding noncompetitive inhibitor of fibroblast collagenase (MMP-1) that engages the enzyme C-terminal domain in an initial rapid step before forming a tight complex [#1], and it also inhibits ADAM-10 with sub-nanomolar potency, distinguishing it from TACE [#0]. This proteolytic activity tunes substrate availability in tissue contexts: TIMP-1 restrains MMP-mediated generation of active HGF to limit Met/p38-driven hepatocyte cell-cycle progression [#2], blocks ADAM-10-mediated shedding of Met to sustain receptor signaling in tumor cells [#4], and limits MMP-9 activity to preserve barrier integrity and matrix structure [#28, #15]. Independently of its MMP-inhibitory domain, TIMP-1 functions as a receptor ligand—principally through the tetraspanin CD63 and its co-receptors β1-integrin and a cell-surface proMMP-9/CD44 complex—to trigger JAK2/PI3K/Akt, FAK, ERK1/2, and Wnt/β-catenin signaling [#3, #6, #7, #11]. Through these axes TIMP-1 promotes anti-apoptotic survival signaling [#3, #17], drives EMT via TWIST1 induction [#5], directs adhesion and chemotaxis of neural stem cells and dendritic cells [#6, #12], stimulates granulopoiesis and neutrophilia [#7], and modulates osteogenic and oligodendrocyte differentiation [#11, #23]. MMP-independence of these signaling outputs is established with structural TIMP-1 mutants lacking inhibitory activity that retain full signaling competence [#5, #7, #17]. Additional surface partners include CD82, which binds the TIMP-1 N-terminus and mediates its endocytosis [#22], and APP/APLP2, engaged via the TIMP-1 C-terminal domain to drive monocyte glucose uptake and proinflammatory cytokine expression [#14]. In stromal and tumor settings TIMP-1 is itself a transcriptional output of TGF-β/SMAD3, NF-κB, ERK1/2, and STAT1/3 signaling, integrating it into reciprocal tumor–stroma crosstalk [#16, #9, #18, #26].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing the kinetic mechanism of TIMP-1 inhibition defined how it neutralizes collagenase, answering whether inhibition was simple competitive blockade or a multi-step process.\",\n      \"evidence\": \"Reconstituted enzyme kinetics with nonlinear regression and C-terminal-truncated mini-collagenase\",\n      \"pmids\": [\"8798626\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address inhibition of other MMP family members\", \"Structural basis of the slow tight-binding transition not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating sub-nanomolar inhibition of ADAM-10 but not TACE extended TIMP-1's target range beyond classical MMPs and defined selectivity among sheddases.\",\n      \"evidence\": \"In vitro quenched fluorescent substrate assay with recombinant catalytic domains\",\n      \"pmids\": [\"10818225\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular consequences of ADAM-10 inhibition not tested here\", \"No structural model of the TIMP-1/ADAM-10 complex\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Dissecting TIMP-1's effect on endothelial migration into MMP-dependent and MMP-independent arms first signaled that TIMP-1 has signaling functions separable from protease inhibition.\",\n      \"evidence\": \"Parallel recombinant TIMP-1 and synthetic MMP inhibitor treatment with FAK/PTEN/paxillin readouts\",\n      \"pmids\": [\"15530852\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating the MMP-independent arm not identified\", \"PTEN induction mechanism unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Reciprocal mouse genetics placed TIMP-1 upstream of HGF/Met/p38 in liver regeneration, showing protease inhibition controls growth factor availability and cell-cycle timing.\",\n      \"evidence\": \"Timp-1 knockout and transgenic overexpression mice with cell-cycle and phospho-Met readouts\",\n      \"pmids\": [\"15726641\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which MMP generates active HGF in vivo not pinpointed\", \"Does not separate inhibitory from signaling contributions\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identifying the surface proMMP-9/CD44 complex as the platform for TIMP-1 anti-apoptotic signaling provided the first defined receptor context for its survival activity.\",\n      \"evidence\": \"Co-IP, proMMP-9 siRNA, MMP-9 blocking antibodies, and survival assays in UT-7 cells\",\n      \"pmids\": [\"19010442\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the ternary complex transduces signal across the membrane unclear\", \"Generalizability beyond erythroid cells untested here\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Two studies linked TIMP-1 to ADAM-10/Met regulation in tumors and to NF-κB-driven anti-apoptotic CD63/Akt signaling, connecting protease inhibition and receptor signaling to cancer cell behavior.\",\n      \"evidence\": \"siRNA knockdown of Timp-1/Adam-10 in liver metastasis model and BRAF/NF-κB epistasis in thyroid carcinoma cells\",\n      \"pmids\": [\"21789719\", \"21903858\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct CD63 binding not structurally mapped in these studies\", \"Single-lab pathway placements\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Multiple studies established that thrombin/STAT1/3, ERK1/2, and NF-κB drive TIMP-1 transcription, and that TIMP-1 governs Reelin processing, topoisomerase phosphorylation, BBB integrity, and CAF expansion, broadening its functional reach.\",\n      \"evidence\": \"EMSA/antisense (STAT), SILAC phosphoproteomics, organotypic epilepsy and ALF models, in vivo CAF assays\",\n      \"pmids\": [\"11918744\", \"23909892\", \"23493620\", \"23532086\", \"24143225\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinase assignments in topoisomerase study are computational\", \"Receptor identity in several contexts not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"CD63 was directly defined as the TIMP-1 receptor driving EMT via TWIST1 and, with β1-integrin, Akt/FAK-dependent migration, anchoring the signaling model with domain mutants proving MMP-independence.\",\n      \"evidence\": \"TIMP-1 overexpression, TWIST1 RNAi rescue, structural MMP-domain mutants, CD63 shRNA, β1-integrin blockade in MCF10A and hNSCs\",\n      \"pmids\": [\"24895412\", \"24635319\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of CD63/β1-integrin co-receptor complex unresolved\", \"Proximal signaling step downstream of CD63 not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Domain-dissecting variants combined with CD63 knockout proved that the CD63-binding signaling domain alone drives granulopoiesis, while Bcl-2 interaction and p90RSK/BAD signaling explain MMP-independent apoptosis suppression.\",\n      \"evidence\": \"CD63 knockout mice, TIMP-1 functional domain variants, BrdU labeling, T2G mutant and Bcl-2 Co-IP, plus TGF-β/CD63/FAK crosstalk in HCC\",\n      \"pmids\": [\"26001794\", \"26366732\", \"26549110\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How CD63 couples to JAK2/Akt versus FAK in different cells unresolved\", \"Direct vs indirect nature of TIMP-1/Bcl-2 interaction not structurally defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"CD82 was identified as a distinct N-terminal-binding partner mediating TIMP-1 endocytosis and anti-migration, expanding the receptor repertoire beyond CD63.\",\n      \"evidence\": \"Co-IP, domain mapping, CD82 siRNA, endocytosis and migration assays in pancreatic carcinoma cells\",\n      \"pmids\": [\"28030805\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relationship between CD82 and CD63 receptor usage unclear\", \"Single-lab finding without reciprocal in vivo validation\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"TIMP-1/CD63 physical interaction was directly confirmed in glioblastoma tissue and shown to couple CD63/β1-integrin to Akt/β-catenin in oligodendrocyte differentiation, reinforcing the receptor model and tying it to Wnt signaling.\",\n      \"evidence\": \"Proximity ligation assay and Co-IP in glioblastoma; pathway inhibitor and receptor-blocking analysis in OPCs\",\n      \"pmids\": [\"29523123\", \"30121936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking CD63 to β-catenin not detailed\", \"Crosstalk with canonical Wnt only partially defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Studies tied TIMP-1/CD63/ITGB1/FAK to pathogen-induced dendritic cell hypermotility and TIMP-1/Wnt/β-catenin to MSC osteogenesis, demonstrating context-dependent suppression or promotion of cell behavior.\",\n      \"evidence\": \"shRNA of TIMP-1/CD63/ITGB1 with FAK/SRC/PI3K inhibitors in DCs; reciprocal TIMP-1 gain/loss with Wnt epistasis in hBMSCs\",\n      \"pmids\": [\"30635444\", \"30473539\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How identical CD63/FAK axis yields opposite migratory outcomes unresolved\", \"Direct receptor for Wnt/β-catenin effect in MSCs not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery of APP/APLP2 as C-terminal-domain TIMP-1 receptors and of ADAMTS-7 as a protease that degrades TIMP-1 added a new signaling axis and a regulatory mechanism controlling TIMP-1 abundance.\",\n      \"evidence\": \"Unbiased ligand-receptor capture, pull-down, confocal and domain variants (APP); Co-IP, in vitro degradation, FRET, and double-KO mice (ADAMTS-7)\",\n      \"pmids\": [\"36629908\", \"37675562\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling from APP/TIMP-1 engagement beyond glucose uptake/cytokines undefined\", \"Physiological breadth of ADAMTS-7-mediated TIMP-1 turnover beyond plaques unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single CD63-centered receptor system selects between Akt, FAK, ERK, and Wnt outputs to produce opposing context-specific phenotypes, and how the protease-inhibitory and cytokine-like functions are coordinated in vivo, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of TIMP-1/CD63/co-receptor signaling complex\", \"Determinants of pro- versus anti-migratory and pro- versus anti-proliferative outcomes unknown\", \"Integration of inhibitory and signaling roles in physiology not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 2, 4, 28]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 30]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [3, 5, 6, 7, 14]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [3, 6, 7, 12, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 3, 19, 29]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 6, 21, 22, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [1, 15, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 6, 7, 11, 12]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [17, 24, 27]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 12, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 23]}\n    ],\n    \"complexes\": [\n      \"TIMP-1/proMMP-9/CD44 ternary complex\",\n      \"CD63/β1-integrin receptor complex\"\n    ],\n    \"partners\": [\n      \"CD63\",\n      \"ITGB1\",\n      \"MMP9\",\n      \"CD44\",\n      \"CD82\",\n      \"APP\",\n      \"APLP2\",\n      \"ADAMTS7\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}